Contact Us
Drug Search Results
More Filters [+]

Dilmapimod

Alternative Names: dilmapimod, sb-681323, sb681323, sb 681323
Latest Update: 2020-12-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: MAPK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dilmapimod

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Arthritis, Rheumatoid|Neuralgia|Chronic Obstructive Pulmonary Disease|Coronary Disease|Coronary Artery Disease|Myocardial Ischemia|Neuropathic Pain|Acute Respiratory Distress Syndrome|Respiratory Distress Syndrome, Newborn|Acute Lung Injury

Phase 1: Chronic Obstructive Pulmonary Disease|Arthritis, Rheumatoid|Inflammation

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT00996840

P2

Completed

Respiratory Distress Syndrome, Newborn|Acute Respiratory Distress Syndrome|Acute Lung Injury

2013-02-09

MKN106762

P2

Completed

Neuralgia|Neuropathic Pain

2008-08-11

2006-001072-21

P2

Completed

Neuropathic Pain

2008-08-11

Type 3C

P1

Completed

Chronic Obstructive Pulmonary Disease

2007-10-26

Recent News Events

Date

Type

Title

12/01/2020

PubMed

 Emerging pharmacological therapies for ARDS: COVID-19 and beyond.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions